Intervention in receptor tyrosine kinase-mediated pathways: Recombinant antibody fusion proteins targeted to ErbB2

Current Topics in Microbiology and Immunology

Volumn 213 III, Issue , 1996, Pages 113-128

  Wels, W ^a   Groner, B ^a   Hynes, N E ^b  

^a TUMOR BIOLOGY CENTER   (Germany)

^b FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; HYBRID PROTEIN; PROTEIN TYROSINE KINASE; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR; TYROSINE KINASE RECEPTOR;

CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0029889079     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80071-9_8     Document Type: Review

References (46)

1. Bacus SS, Gudkov AV, Zelnik CR, Chin D, Stern R, Stancovski I, Peles E, Ben-Baruch N, Farbstein H, Lupu R, Wen D, Sela M, Yarden Y (1993) Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors Cancer Res 53: 5251-5261
2. Beerli RR, Wels W, Hynes NE (1994a) Intracellular expression of single chain antibodies reverts ErbB-2 transformation. J Biol Chem 269. 23931-23936
3. Beerli RR, Wels W, Hynes NE (1994b) Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody. Biochem Biophys Res Commun 204: 666-672
4. Carraway KL, Cantley LC (1994) A neu acquaintance for ErbBS and ErbB4: a role for receptor heterodimenzation in growth signaling. Cell 78: 5-8
5. Chang AE, Shu S (1992) Immunotherapy with sensitized lymphocytes Cancer Invest 10: 357-369
6. Colomer R, Lupu R, Bacus SS, Gelmann EP (1994) ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification Br J Cancer 70: 819-825
7. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719
8. Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI (1994) The neuoncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9: 2109-2123
9. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90. 720-724
10. Goldberg MR, Heimbrook DC, Russo P, Sarosdy MF, Greenberg RE, Giantonio BJ, Linehan WM, Walther M, Fisher HAG, Messing E, Crawford ED, Oliff AE, Pastan IH (1995) Phase I clinical study of the recombinant oncotoxin TP40 in superficial bladder cancer. Clin Cancer Res 1. 57-61
11. Graus-Porta D, Beerli RR, Hynes NE (1995) Single-chain antibody-mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 15: 1182-1191
12. Harwerth IM, Wels W, Marte BM, Hynes NE (1992) Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists J Biol Chem 267: 15160-15167
13. Harwerth IM, Wels W, Schlegel J, Müller M, Hynes NE (1993) Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth Br J Cancer 68: 1140-1145
14. Howe LR, Weiss A (1995) Multiple kinase mediate T-cell-receptor signaling. Trends Biochem Sci 20: 59-64
15. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor Mol Cell Biol 9 1165-1172
16. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198 165-184
17. Jeschke M, Wels W, Dengler W, Imber R, Stöcklin E, Groner B (1995) Targeted inhibition of tumor cell growth by recombinant heregulin-toxin fusion proteins. Int J Cancer 60: 730-739
18. Kasprzyk PG, Song SU, DiFiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies Cancer Res 52 2771-2776
19. Kast MW, Offringa R, Peters PJ, Voordouw AC, Meloen RH, van der Eb AJ, Melief CJM (1989) Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell 59. 603-614
20. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91 6458-6462
21. Kornilova ES, Taverna D, Hoeck W, Hynes NE (1992) Surface expression of erbB-2 protein is post-transcriptionally regulated in mammary epithelial cells by epidermal growth factor and by the culture density. Oncogene 7: 511-519
22. Messerle K, Schlegel J, Hynes NE, Groner B (1994) NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. Mol Cell Endocrinol 105: 1-10
23. Moritz D, Groner B (1995) A spacer region between the single chain antibody and the CD3 ζ-chain domain of chimeric T-cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 2: 539-546
24. Moritz D, Wels W, Mattern J, Groner B (1994) Cytotoxic T lymphocytes with a grafted recognition specificity for erbB-2 expressing tumor cells Proc Natl Acad Sci USA 91: 4318-4322
25. Munro S, Pelham HRB (1987) A C-terminal signal prevents secretion of luminal ER proteins. Cell 48: 899-907
26. Pai LH, Gallo MG, FitzGerald DJ, Pastan I (1991) Antitumor activity of a transforming growth factor α-Pseudomonas exotoxin fusion protein (TGF-α-PE40). Cancer Res 51: 2808-2812
27. Pastan I, FitzGerald D (1991) Recombinant toxins for cancer treatment. Science 254: 1173-1177
28. Peles E, Yarden Y (1993) Neu and its ligands: from an oncogene to neural factors. Bioassays 15: 815-824
29. Press MF, Cordon-Cardo C, Slamon DJ (1990) Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5: 953-962
30. Romeo C, Seed B (1991) Cellular Immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64. 1037-1046
31. Rosenberg SA (1991) Immunotherapy and gene therapy of cancer. Cancer Res 51: 5074s-5079s
32. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492
33. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seippe CA (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319: 1676-1680
34. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232
35. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M (1991) Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 88: 8691-8695
36. Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D, Yarden Y (1994) ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all neu differentiation factor/heregulin isoforms. J Biol Chem 269: 25226-25233
37. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eyde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254 1643-1647
38. Van De Vijver MJ, Kumar R, Mendelsohn J (1991) Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly J Biol Chem 266 7503-7508
39. Wegener AM, Letourneur F, Hoeveler A, Brocker T, Luton F, Malissen B (1992) The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules Cell 68. 83-95
40. Wels W, Harwerth IM, Hynes NE, Groner B (1992a) Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor J Steroid Biochem Mol Biol 43. 1-7
41. Wels W, Harwerth IM, Müller M, Groner B, Hynes NE (1992b) Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res 52 6310-6317
42. Wels W, Harwerth IM, Zwickl M, Hardman N, Groner B, Hynes NE (1992c) Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology 10 1128-1132
43. erbB-2 specific single-chain antibody-toxins differ in their cell killing activity on tumor cells expressing both receptor proteins Int J Cancer 60. 137-144
44. Wels W, Moritz D, Schmidt M, Jeschke M, Hynes NE, Groner B (1995b) Biotechnological and gene therapeutic strategies in cancer treatment. Gene 159. 73-80
45. Winter G, Milstein C (1991) Man-made antibodies. Nature 349: 293-299
46. Zdanovsky AD, Chiron M, Pastan I, FitzGerald DJ (1993) Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step. J Biol Chem 268. 21791-21799